{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:01:20Z","timestamp":1791050480865,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":275,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1124\/jpet.123.001900","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T22:10:16Z","timestamp":1708985416000},"page":"61-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease"],"prefix":"10.1016","volume":"389","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-7848","authenticated-orcid":false,"given":"David","family":"Hollenback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hambruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Birkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hornberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly MacLennan","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Desiree","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Steeneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Kinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Liles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Budas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kremoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001900_bib1","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/ijms20102586","article-title":"The Biology of the Nuclear Envelope and Its Implications in Cancer Biology","volume":"20","author":"Alvarado-Kristensson","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.123.001900_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.123.001900_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib4","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/1873-3468.14478","article-title":"A novel approach to single-cell analysis reveals intrinsic differences in immune marker expression in unstimulated BALB\/c and C57BL\/6 macrophages","volume":"596","author":"Breda","year":"2022","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.123.001900_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.123.001900_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001900_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/me.2014-1337","article-title":"Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity","volume":"29","author":"Cheng","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1124\/jpet.123.001900_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.123.001900_bib9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/jpet.123.001900_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1124\/jpet.123.001900_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med Mol Morphol"},{"key":"10.1124\/jpet.123.001900_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.123.001900_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0022-2275(20)39310-X","article-title":"QUANTITATIVE ISOLATION AND GAS--LIQUID CHROMATOGRAPHIC ANALYSIS OF TOTAL FECAL BILE ACIDS","volume":"6","author":"Grundy","year":"1965","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.123.001900_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-\/-) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001900_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","article-title":"Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis","volume":"20","author":"Hansen","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1124\/jpet.123.001900_bib17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001900_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/sj.embor.7401075","article-title":"The inner nuclear envelope as a transcription factor resting place","volume":"8","author":"Heessen","year":"2007","journal-title":"EMBO Rep"},{"key":"10.1124\/jpet.123.001900_bib19","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.123.001900_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.123.001900_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.mad.2013.08.003","article-title":"Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice","volume":"134","author":"Jiang","year":"2013","journal-title":"Mech Ageing Dev"},{"key":"10.1124\/jpet.123.001900_bib22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1126\/science.aaz4427","article-title":"Partitioning of cancer therapeutics in nuclear condensates","volume":"368","author":"Klein","year":"2020","journal-title":"Science"},{"key":"10.1124\/jpet.123.001900_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile Acids as Hormones: The FXR-FGF15\/19 Pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"key":"10.1124\/jpet.123.001900_bib24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: How are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"10.1124\/jpet.123.001900_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.123.001900_bib30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/ph16050758","article-title":"Structure Optimization of 12\u03b2-O-\u03b3-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist\/Modulator for NASH Therapy","volume":"16","author":"Ma","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/jpet.123.001900_bib31","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1124\/jpet.123.001900_bib32","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.001900_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.123.001900_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"10.1124\/jpet.123.001900_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-2275(20)39311-1","article-title":"QUANTITATIVE ISOLATION AND GAS--LIQUID CHROMATOGRAPHIC ANALYSIS OF TOTAL DIETARY AND FECAL NEUTRAL STEROIDS","volume":"6","author":"Miettinen","year":"1965","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.123.001900_bib36","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J Immunol"},{"key":"10.1124\/jpet.123.001900_bib37","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.2741\/3563","article-title":"Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio","volume":"14","author":"Modica","year":"2009","journal-title":"Front Biosci"},{"key":"10.1124\/jpet.123.001900_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00125-013-2846-8","article-title":"Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding","volume":"56","author":"Montgomery","year":"2013","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.123.001900_bib39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001900_bib40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS\u2013) vs. Alternatively Activated Macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.123.001900_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.123.001900_bib42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1124\/jpet.123.001900_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib44","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib45","doi-asserted-by":"crossref","DOI":"10.11131\/2015\/101178","article-title":"Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions","volume":"2","author":"Prakash","year":"2015","journal-title":"Nucl Receptor Res"},{"key":"10.1124\/jpet.123.001900_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/574832","article-title":"Nonalcoholic Steatohepatitis: A Search for Factual Animal Models","volume":"2015","author":"Sanches","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1124\/jpet.123.001900_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/liv.12456","article-title":"Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal","volume":"35","author":"Schmitt","year":"2015","journal-title":"Liver Int"},{"key":"10.1124\/jpet.123.001900_bib49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/biomedicines9010060","article-title":"The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1124\/jpet.123.001900_bib50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/cells8080915","article-title":"The NAE Pathway: Autobahn to the Nucleus for Cell Surface Receptors","volume":"8","author":"Shah","year":"2019","journal-title":"Cells"},{"key":"10.1124\/jpet.123.001900_bib52","doi-asserted-by":"crossref","first-page":"14052","DOI":"10.1038\/s41598-020-70765-w","article-title":"C57BL\/6J substrain differences in response to high-fat diet intervention","volume":"10","author":"Siersb\u00e6k","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.123.001900_bib53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.1840080429","article-title":"Feedback regulation of bile acid synthesis in the rat by dietary vs. intravenous cholate or taurocholate","volume":"8","author":"Stange","year":"1988","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bpg.2011.02.004","article-title":"Animal models for the study of hepatic fibrosis","volume":"25","author":"Starkel","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1124\/jpet.123.001900_bib55","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/labinvest.2010.107","article-title":"Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice","volume":"90","author":"Stroeve","year":"2010","journal-title":"Lab Invest"},{"key":"10.1124\/jpet.123.001900_bib56","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-Label Extension in Patients with PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.123.001900_bib57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients with Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1124\/jpet.123.001900_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib59","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - Is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.123.001900_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","article-title":"FXR modulators for enterohepatic and metabolic diseases","volume":"28","author":"Wang","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.123.001900_bib61","first-page":"R1025","article-title":"Dietary obesity in nine inbred mouse strains","volume":"262","author":"West","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.123.001900_bib62","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3748\/wjg.v18.i36.4985","article-title":"Novel insight into mechanisms of cholestatic liver injury","volume":"18","author":"Woolbright","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1124\/jpet.123.001900_bib63","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ydbio.2004.02.003","article-title":"Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction","volume":"269","author":"Wright","year":"2004","journal-title":"Dev Biol"},{"key":"10.1124\/jpet.123.001900_bib64","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001900_bib65","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:18:15Z","timestamp":1739978295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524172266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022356524172266"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001900","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Author(s)","name":"copyright","label":"Copyright"}]}}